ArticleClinical practice and epidemiology in mental health : CP & EMH2025
Objective Assessment of Attention Deficit Hyperactivity Disorder with QbMobile: A Smartphone Application for Clinical Use.
Article in Clinical practice and epidemiology in mental health : CP & EMH, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Digital mental health interventions such as web or mobile applications have become more prominent in the last years to improve the clinical assessment and workflow in mental health disorders while also being potentially more accessible than laptops. QbMobile is a software application that provides objective assessments of hyperactivity, impulsivity, and inattention to aid in the clinical evaluation of attention deficit hyperactivity disorder (ADHD). The purpose was to examine whether QbMobile could objectively quantify symptoms and reveal significant clinical differences between an ADHD population and a normative population. Methods: Data were acquired from two low-intervention/observational studies (conducted in Europe and US), involving participants aged 6 to 60 years. The application (QbMobile) was configured on the smartphone (iPhone) with embedded instructions to ensure a consistent experience. Participants were seated at a desk in a stabilized chair and instructed to hold the smartphone with both hands and to tap the screen whenever an infrequent target stimulus appeared, while withholding a response to non-target stimuli. Concurrently, to measure activity, the camera of the smartphone captured the physical activity of the participant as well as the movements from holding the device. Approximately 20% of the complete dataset for each study was combined as a pooled dataset for a model validation of output parameters from QbMobile. A Total Score between 0 and 100 was calculated, where lower scores indicate a lower likelihood of ADHD symptoms and higher scores indicate a higher likelihood. Results: The ADHD cohort (n=63) demonstrated a higher mean Total Score of 83.0 (Standard deviation=17.5) compared to 48.9 (Standard deviation=18.8) in the normative population (n=354), a difference that was statistically significant (p<0.001). Significant domain-specific differences in SD-scores (movement pattern, activity, impulsivity, inattention) were identified between the ADHD cohort and the normative comparison group (p<0.001). A sensitivity of 0.86 and specificity of 0.75 were seen overall, though a low specificity was found in children, which was likely due to a smaller sample size and high activity levels in younger children in general. Discussion: This investigation demonstrates that QbMobile can generate objective symptom measurements that distinguish clinically relevant differences between individuals with ADHD and a normative population. A smartphone application of quantified behavioral psychometric testing of the core symptoms could streamline a faster diagnostic evaluation and treatment titration in the ADHD clinical workflow. The authors are employed by the manufacturer of QbMobile, which is discussed in this manuscript. This affiliation is disclosed to ensure transparency and does not affect the objectivity or scientific integrity of the work presented. Conclusion: QbMobile demonstrated the ability to differentiate between ADHD and normative cohorts, indicating its potential as an accessible and objective tool for clinical assessment and treatment evaluation. Future studies should be conducted to further validate the effectiveness of QbMobile as an aid tool in the clinical assessment of ADHD and further explore its use in various populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.